Eli Lilly's Stock Tumbles 15% After Disappointing Obesity Pill Trial Results
Eli Lilly's shares dropped 15% after its obesity pill, orforglipron, failed in Phase III trials, failing to compete with Novo Nordisk's Ozempic, despite positive earnings.
Ozempic News
Novo Nordisk Reports Impressive 13% Sales Growth in Q2 2025, Despite Lowered Full-Year Guidance
Novo Nordisk A/S reports a 13% increase in Q2 2025 sales to 76.9 billion Danish kroner, with net profit up by 32%. The company has lowered its full-year sales growth forecast due t...
Novo Nordisk Faces Share Drop Amid Ozempic Vision Safety Concerns
Novo Nordisk's shares dropped over 2% after a preprint study linked Ozempic to a rare vision condition. The study, by scholars from Norway and Denmark, found Ozempic users were twi...
